Technical Analysis for INCY - Incyte Corporation

Grade Last Price % Change Price Change
grade B 86.73 0.03% 0.03
INCY closed up 1.06 percent on Friday, November 15, 2019, on 1.23 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical INCY trend table...

Date Alert Name Type % Chg
Boomer Buy Setup Bullish Swing Setup 0.03%
Pocket Pivot Bullish Swing Setup 0.03%
NR7 Range Contraction 0.03%
Inside Day Range Contraction 0.03%
Overbought Stochastic Strength 0.03%
Bearish Engulfing Bearish 1.10%
Inside Day Range Contraction 1.10%
Overbought Stochastic Strength 1.10%
Pocket Pivot Bullish Swing Setup -0.80%
Overbought Stochastic Strength -0.80%

Older signals for INCY ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. The company markets JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, a JAK inhibitor, which is in Phase III clinical trial for polycythemia vera; Phase II trial for essential thrombocythemia; Phase II trial for pancreatic cancer; Phase I/II trial to treat solid tumors/other hematologic malignancies, as well as baricitinib, a JAK inhibitor, which is Phase III trial for rheumatoid srthritis, Phase IIb trial for psoriasis, and Phase II trial for diabetic nephropathy. The company's products in pipeline also comprise INCB28060 and INCB24360, which are Phase II clinical trial products for the treatment of solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Chemistry Biopharmaceutical Chemical Compounds Organic Compounds Solid Tumors Inflammation Psoriasis Pancreatic Cancer Diabetic Nephropathy Janus Kinase Inhibitor Myelofibrosis Clinical Trial Products Nitriles Sulfonamides
Is INCY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 89.3
52 Week Low 57.0
Average Volume 1,007,068
200-Day Moving Average 81.1665
50-Day Moving Average 79.0212
20-Day Moving Average 82.782
10-Day Moving Average 85.102
Average True Range 2.1206
ADX 36.25
+DI 25.7099
-DI 8.7048
Chandelier Exit (Long, 3 ATRs ) 81.4782
Chandelier Exit (Short, 3 ATRs ) 82.6318
Upper Bollinger Band 89.0572
Lower Bollinger Band 76.5068
Percent B (%b) 0.81
BandWidth 15.160784
MACD Line 2.2306
MACD Signal Line 1.9404
MACD Histogram 0.2902
Fundamentals Value
Market Cap 17.84 Billion
Num Shares 206 Million
EPS -0.79
Price-to-Earnings (P/E) Ratio -109.75
Price-to-Sales 18.19
Price-to-Book 23.14
PEG Ratio -1.27
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 88.56
Resistance 3 (R3) 88.53 87.88 88.25
Resistance 2 (R2) 87.88 87.41 87.90 88.15
Resistance 1 (R1) 87.29 87.11 87.59 87.32 88.04
Pivot Point 86.64 86.64 86.79 86.66 86.64
Support 1 (S1) 86.05 86.17 86.35 86.08 85.36
Support 2 (S2) 85.40 85.87 85.42 85.25
Support 3 (S3) 84.81 85.40 85.15
Support 4 (S4) 84.84